Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

50. (Original) A drug-oligomer conjugate having the following general formula:

$$D\text{-}[(H\text{-}H'_q)\text{-}L_o]_p \qquad \text{(Formula 10)}$$

wherein

D is insulin or a functional equivalent thereof;

H is a PEG polymer having from 1 to 10 PEG units;

H' is a hydrophilic moiety;

L is a lipophilic moiety;

the H-H' bond is hydrolyzable;

q is a number from 1 to the maximum number of covalent bonding sites at which H' can form a bond with H;

o is a number from 1 to the maximum number of covalent bonding sites at which L can form a bond with H'; and

p is a number from 1 to the maximum number of covalent bonding sites at which $-[(H\text{-}H'_q)\text{-}L_o]$ can form a bond with D.

51. (Original) The drug-oligomer conjugate of Claim 50, wherein H, H' and L are selected and arranged such that the drug-oligomer conjugate is amphiphilic.

52. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having from 2 to 8 PEG units.

53. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having from 2 to 7 PEG units.

54. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 3 PEG units.

55. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 4 PEG units.

56. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 5 PEG units.

57. (Original) The drug-oligomer conjugate of Claim 50, wherein H is a PEG polymer having 6 PEG units.

58. (Original) The drug-oligomer conjugate of Claim 50, wherein H' is a hydrophilic moiety selected from the group consisting of straight or branched PEG polymers and sugars.

59. (Original) The drug-oligomer conjugate of Claim 50, wherein H' is a straight PEG polymer.

60. (Original) The drug-oligomer conjugate of Claim 59, wherein the PEG polymer has from 1 to 130 PEG units.

61. (Original) The drug-oligomer conjugate of Claim 59, wherein the PEG polymer has from 1 to 100 PEG units.

62. (Original) The drug-oligomer conjugate of Claim 50, wherein L is a lipophilic moiety selected from the group consisting of alkyl moieties, cholesterol, and fatty acid moieties.

63. (Original) The drug-oligomer conjugate of Claim 50, wherein L is an alkyl moiety.

64. (Original) The drug-oligomer conjugate of Claim 50, wherein L is cholesterol.

65. (Original) The drug-oligomer conjugate of Claim 50, wherein L is a fatty acid moiety.

66. (Original) The drug-oligomer conjugate of Claim 65, wherein the fatty acid moiety has between 2 and 28 carbon atoms.

67. (Original) The drug-oligomer conjugate of Claim 65, wherein the fatty acid moiety has between 12 and 22 carbon atoms.

68. (Original) The drug-oligomer conjugate of Claim 50, wherein D is insulin or insulin lispro.

69. (Original) The drug-oligomer conjugate of Claim 50, wherein the H'-L bond is non-hydrolyzable.

70. (Original) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $CH_3(CH_2)_n(OC_2H_4)_mOH$ (Formula 3), wherein n = 3 to 25 and m = 1 to 7.

71. (Original) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $CH_3(CH_2)_n(OC_2H_4)_mOCH_2CO_2H$ (Formula 4), wherein n = 3 to 25 and m = 1 to 6.

72. (Original) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $R\text{-}(OC_2H_4)_mCH_2CO_2H$ (Formula 6), wherein m = 0 to 5 and R = cholesterol or adamantine

73. Cancelled.

74. (Original) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $CH_3(CH_2\text{-}CH{=}CH)_6(CH_2)_2CH_2(OC_2H_4)_mOH$ (Formula 8), wherein m = 1 to 7.

75. (Original) The drug-oligomer conjugate of claim 50, wherein H' and L are present as a component H'-L having the formula $CH_3(CH_2\text{-}CH{=}CH)_6(CH_2)_2CX(OC_2H_4)_mOH$ (Formula 9), wherein m = 1 to 7.